Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, et al. Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer discovery. 2025. 15. 1. 119-138
Takeshi Hirose, Masachika Ikegami, Kumiko Kida, Toshihide Ueno, Rina Kitada, Lei Wang, Shinya Tanaka, Makoto Endo, Yasuharu Nakashima, Naoki Kanomata, et al. Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling. NPJ breast cancer. 2024. 10. 1. 87-87
Hidenori Kage, Shinji Kohsaka, Kenji Tatsuno, Kousuke Watanabe, Aya Shinozaki-Ushiku, Hideaki Isago, Tetsuo Ushiku, Hiroyuki Aburatani, Hiroyuki Mano, Katsutoshi Oda. Molecular analysis of non-small cell lung cancer using a dual-targeted DNA and RNA comprehensive genomic profiling panel. Respiratory investigation. 2024. 62. 5. 910-913
Hiroshi Ikeuchi, Yusuke Matsuno, Rika Kusumoto-Matsuo, Shinya Kojima, Toshihide Ueno, Masachika Ikegami, Rina Kitada, Hitomi Sumiyoshi-Okuma, Yuki Kojima, Kan Yonemori, et al. GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene. 2024
Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, Shinji Kohsaka. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Cancer medicine. 2024. 13. 12. e7351